Microbot Medical® Highlights Growth Strategy

The sales footprint is growing, while positive gross margins remain a company expectation for 2027.

Rhea-AI Summary

Microbot Medical (MBOT) reported its first California customer while outlining U.S. sales expansion at a September 24, 2026, analyst meeting.

The company is targeting 12 sales territories by year-end and is expanding in North Carolina. It hired three Area Sales Managers and one Regional Sales Director and is engaging hospital value analysis committees at multiple health systems. The company described a user survey as showing high satisfaction with its LIBERTY System.

Microbot expects manufacturing changes, including a second line, to produce positive gross margins in 2027. CE mark approval is expected in late Q4 2026 or early Q1 2027. Potential expansion into parts of Asia and the Middle East is in advanced stages.

Market Context

On Jul 07, the Q2 growth report accompanied a 1.55% decline; its disclosed territory expansion and r...

Analysis

On Jul 07, the Q2 growth report accompanied a 1.55% decline; its disclosed territory expansion and revenue growth provide commercial-rollout context for this update, though that reaction alone does not establish a pattern.

Key Figures

Sales territories: 12 territories Value Analysis Committee process: Four to six months Gross margin outlook: Positive gross margins +2 more

Sales territories

12 territories

Company target by year-end

Value Analysis Committee process

Four to six months

Duration based on the company's current experience

Gross margin outlook

Positive gross margins

Company expects this in 2027

CE mark approval outlook

Late Q4 2026 or early Q1 2027

Company expectation

California customer

First customer

Company's expansion into California

Historical Context

3 past events · Latest: Aug 11

3 events

1. Aug 11

   Commercial growth

   24h Move

   -13.2%

   Q2 revenue and customer counts grew over 100%; sales footprint expanded from four to eight territories.

2. Jul 07

   Commercial growth

   24h Move

   -1.6%

   Q2 revenue and new customers grew over 100%, while U.S. sales territories doubled.

3. Jun 30

   Manufacturing agreement

   24h Move

   +4.3%

   Sanmina agreement added manufacturing capacity through a second LIBERTY production site.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

value analysis committee, ce mark, fda clearance, endovascular

4 terms

value analysis committee technical

"Value Analysis Committee (VAC) process earlier"

A value analysis committee is a group within a healthcare provider or hospital that evaluates medical products, devices, supplies, or procedures to judge their clinical effectiveness, safety, and cost implications before the organization buys or uses them. Think of it as a buying panel that balances quality and cost to decide which options deliver the best overall value. Its decisions matter to investors because they can affect a supplier’s sales, product adoption, and pricing in healthcare markets.

ce mark regulatory

"future CE mark approval"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

fda clearance regulatory

"where the Company can leverage its FDA clearance"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

endovascular medical

"robotic system for peripheral endovascular procedures"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

User Survey Demonstrates High Satisfaction of the LIBERTY System

Expansion of Sales Footprint Expands to Western U.S. as Company Secures First California Customer

HINGHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it highlighted the continuation of its commercial and growth strategy during an analyst meeting held in New York City on Thursday, September 24, 2026. The Company also highlighted select results from a user survey, available on the Company’s website, conveying high satisfaction with the system.

Key Topics Discussed:

• Expansion of the U.S. footprint is continuing, and the Company is on track to have 12 sales territories by the end of the year, to accelerate growth and support the Company’s first customer in California and its expansion in North Carolina.
• The Company’s commercial strategy has evolved to engage Value Analysis Committee (VAC) process earlier, a four-to-six-month process based on the Company’s current experience, to gain widespread access to hospital systems. The Company believes this approach will accelerate adoption of the LIBERTY System across healthcare systems with multiple hospitals. The Company is now engaged with the VAC at multiple health systems.
• Hired three additional Area Sales Managers and an additional Regional Sales Director to focus on new sales territories and expand west.
• The Company continues to advance and focus on operating efficiencies, such as adding a second manufacturing line and moving to more efficient manufacturing processes, which the Company expects will result in positive gross margins in 2027.
• Potential expansions to certain international markets, including in Asia and the Middle East, where the Company can leverage its FDA clearance, are in advanced stages, while the Company continues its engagement with regulatory bodies to support future CE mark approval which is expected in late Q4 2026 or early Q1 2027.
  

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How is Microbot Medical seeking wider hospital access for the LIBERTY System?

Microbot Medical is engaging value analysis committees at multiple health systems earlier in its sales process. Based on its current experience, the committee process takes four to six months. The company believes earlier engagement will accelerate adoption across health systems with multiple hospitals.